Pfizer Inc. Wednesday raised its forecast for sales of the Kovid-19 vaccine developed with Germany biontech 28.8% to $33.5 billion, as countries scramble to secure a supply of shots.
The company said its forecast of increased sales of the vaccine is based on deals it signed for 2.1 billion doses this year, and could increase if it signs additional contracts. Pfizer and BioNTech expect to produce 3 billion doses of the vaccine this year.
Pfizer made a major debut in December with the first US emergency authorization of a COVID-19 vaccine, and has since overtaken rivals that have faced manufacturing bottlenecks. The safety of Johnson & Johnson’s vaccine is also being investigated.
J&J last week estimated sales of the Kovid-19 vaccine for the full year at $2.5 billion, while Modern estimated at $19.2 billion.
Pfizer has said it believes a third “booster” dose of its vaccine will be needed in the future, which could help drive more sales in 2022. The company said Wednesday that it may file for emergency use authorization for a potential booster dose. As early as August.
Top infectious disease official Anthony Fauci said on Sunday that Americans whose immunity is compromised may need booster shots as the United States deals with rising cases from the delta version of the coronavirus.
The United States bought 200 million more doses Pfizer/BioNTech Vaccines last week to help with pediatric immunizations as well as potential booster shots – if they are needed.
Pfizer’s previous forecast of $26 billion in May was based on deals signed for 1.6 billion doses. Wall Street stood at $28.51 billion, roughly in line with that forecast, according to nine analysts surveyed by Refinitiv.
Vaccine costs and profits are split 50-50 between Pfizer and BioNTech.
The company said its forecast of increased sales of the vaccine is based on deals it signed for 2.1 billion doses this year, and could increase if it signs additional contracts. Pfizer and BioNTech expect to produce 3 billion doses of the vaccine this year.
Pfizer made a major debut in December with the first US emergency authorization of a COVID-19 vaccine, and has since overtaken rivals that have faced manufacturing bottlenecks. The safety of Johnson & Johnson’s vaccine is also being investigated.
J&J last week estimated sales of the Kovid-19 vaccine for the full year at $2.5 billion, while Modern estimated at $19.2 billion.
Pfizer has said it believes a third “booster” dose of its vaccine will be needed in the future, which could help drive more sales in 2022. The company said Wednesday that it may file for emergency use authorization for a potential booster dose. As early as August.
Top infectious disease official Anthony Fauci said on Sunday that Americans whose immunity is compromised may need booster shots as the United States deals with rising cases from the delta version of the coronavirus.
The United States bought 200 million more doses Pfizer/BioNTech Vaccines last week to help with pediatric immunizations as well as potential booster shots – if they are needed.
Pfizer’s previous forecast of $26 billion in May was based on deals signed for 1.6 billion doses. Wall Street stood at $28.51 billion, roughly in line with that forecast, according to nine analysts surveyed by Refinitiv.
Vaccine costs and profits are split 50-50 between Pfizer and BioNTech.
.